Background Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the gut, most commonly presenting as Crohn's Disease (CD) and Ulcerative Colitis (UC). Over the last 12 months, our team in Cochrane Gut has worked with the UK British Gastroenterology Society (BSG) and Crohn's and colitis UK (CCUK) to examine key priority publications and then refine them into this programme to address only the most contemporaneous review gaps within the field. The COVID-19 pandemic has switched clinical work to remote telehealth options, as well as increasing demand for patient education to support self-management, but no synthesis of these techniques exists. With an increasing range of biologic options for CD, up to date synthesis to compare the full range of options is needed. However, biologics have also been a key concern during their pandemic, as there is a recognised infection risk with their use. Finally, many patients are interested in dietary supplements to change their symptoms and this represents a gap in the current Cochrane portfolio. Aims and objectives The scope of the programme will address these aims: - What is the efficacy and safety of patient education and remote management of IBD care? - What is the efficacy and safety of biologic and immunosuppressant therapies for Crohn's disease? - What is the efficacy and safety of supplements to normal diet for IBD? Methods This programme of 8 Cochrane reviews of varying size, scope and complexity will include three update reviews, five new titles including one network meta-analysis. A steering group will be established. The core team will consist of the Chief investigator, a full time experienced Cochrane reviewer, a senior researcher and a member of the CCUK patient information editorial board. All staff are in post and their time seconded, allowing timely project establishment. We will prioritise the reviews that will have direct impact during the COVID-19 pandemic. We will ensure the scope and outcome measures for every review are considered by the steering group. The Cochrane Gut group structure offers the support of our colleagues in the second Canadian base of the group for all editorial and review duties in an expedited fashion. Timelines for delivery In the first 3 months of the project the team will complete all protocols. Two of the new protocols are already in the final stage of peer review at time of this proposal submission. The core review work will be completed over 12 months, with the reviews grouped in three blocks by theme. Whist the grant is not supporting core CRG activity, the wider group allows significant contingency to ensure successful delivery of the programme. Anticipated impact and dissemination As well as the 8 published reviews, findings will be fed-back to the key stakeholder organisations to support prompt uptake. In particular, continuing our close working relationship established with CCUK and BSG, we will support their Knowledge & Evidence team and IBD committees respectively in updating relevant patient information and guidance for UK users. Additionally, keynote sessions at major scientific meetings are in place offer another route to dissemination, with most already shifting to virtual formats to continue during the pandemic. Finally, we have shared publication agreements with key journals in the field.